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Abstract
Background: Hypertension constitutes a growing burden of illness in developing countries like Zambia. Adequately
screening and treating hypertension could greatly reduce the complications of stroke and coronary disease. Our
objective was to determine the prevalence of hypertension and identify current treatment practices among adult
patients presenting for routine care to rural health facilities in the Better Health Outcomes through Mentoring and
Assessments (BHOMA) project.
Methods: We conducted a retrospective analysis of routinely collected clinical data from 46 rural government
clinics in Zambia. Our analysis cohort comprised patients ≥ 25 years with recorded blood pressure measurements,
who sought care at primary health centers. Consistent with prior research, in our primary analysis, we only included
data from first visits. Hypertension was defined as a systolic blood pressure ≥140 mmHg, or diastolic blood pressure
≥90 mmHg, or reported use of antihypertensive medication. A sensitivity analysis was performed using median
blood pressure for individuals with multiple visits.
Results and Discussion: From January 2011 to December 2014, 116,130 first visits by adult patients met eligibility
criteria. The crude prevalence of hypertension by onsite measurement or reported use of antihypertensive
medication was 23.1 % [95 % CI: 22.8-23.3] (23.6 % in females, 22.3 % in males). The age standardized prevalence of
hypertension across participating sites was 28.0 % [95 % CI: 27.7-28.3] (29.7 % in females, 25.8 % in males).
Sensitivity analysis revealed a similar prevalence using data from all visits. Only 5.6 % of patients had a diagnosis of
hypertension documented in their medical record. Among patients with hypertension, only 18.0 % had any
antihypertensive drug prescribed, with nifedipine (8.9 %), furosemide (8.3 %), and propranolol (2.4 %) as the most
common.
Conclusions: Age standardized prevalence of hypertension in rural primary health clinics in Zambia was high
compared to other studies in rural Africa; however, we diagnosed hypertension with only one measurement and this
may have biased our findings. Future efforts to improve hypertension control should focus on population preventive
care and primary healthcare provider education on individual management.
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Background
Hypertension and its long term consequences constitute
a growing burden in developing countries, with as much
as 75 % of all affected patients now living in low- and
middle- income countries (LMIC) [1–5]. Defined by the
World Health Organization as a blood pressure meas-
urement ≥140/90 mmHg, hypertension is a major
known risk factor for chronic conditions such as cardio-
vascular disease, hemorrhagic stroke, and renal failure
[1, 6–9]. According to the 2012 WHO Global Health
Observatory, 46 % of deaths in LMIC are attributable to
cardiovascular disease (CVD) [10]. Notably, CVD deaths
occur in sub-Saharan Africa at a younger mean age
(64.9 years) than anywhere else in the world [7].
In Zambia, non-communicable diseases (NCDs) ac-
count for up to a quarter of all deaths, with about half of
these due to CVDs [11]. As life expectancy increases,
this burden is expected to rise as well. There is a paucity
of epidemiologic data on hypertension prevalence and
treatment in Zambia [12, 13]. Like the vast majority of
studies in sub-Saharan Africa, past studies in Zambia
have used cross-sectional community survey designs
with a single blood pressure (BP) measurement to define
hypertension [12–15]. To date, there are no studies
examining the profile of hypertension patients who actu-
ally present to primary health clinics. Similarly, while
control of hypertension with appropriate medication can
greatly reduce complications like stroke and other car-
diovascular events [16], there are very few studies that
have examined and reported treatment practices.
To address these gaps, we sought to determine the age
standardized prevalence and existing treatment practices
of hypertension in 46 Zambian rural primary health care
centers participating in the Better Health Outcomes
through Mentoring and Assessment (BHOMA) interven-
tion [17].
Methods
The BHOMA project is a five-year, randomized stepped-
wedge trial of improved clinical service delivery underway
in 46 rural clinics in Chongwe, Kafue, and Luangwa
Districts. The public sector lacks robust healthcare infra-
structure and suffers from a severe human resource short-
age, with only 0.7 physicians and 7.8 nurses per 10,000
people [18]. A number of our selected rural clinics are
staffed by one nurse or clinical officer, and frequently
suffer from equipment shortage. BHOMA has five princi-
pal objectives: 1) creating standardized protocols and
forms for common primary care visits, 2) ensuring clinics
are properly equipped with essential diagnostic and
management tools, 3) on site electronic medical records
(EMR), 4) improving key indicators with ongoing mentor-
ing, and 5) increasing community engagement with com-
munity health workers and traditional birth attendants
[17]. This study is an analysis of the observational EMR
database.
Participants and data collection
First primary care visits by adults ≥25 years with a blood
pressure measurement were included, to collapse the
longitudinal database into a cross-sectional sample. Age
bands from 0–25 years were dropped in calculations
consistent with prior studies [9]. BHOMA intervention
began in Aug 2010 in six pilot primary health facilities,
and Apr 2011 in 40 primary health facilities, with current
ongoing follow up. The EMR database was operational
starting Jan 2011 and captures data from all clinic visits by
children and adults; thus all data from Jan 2011 to Dec
2014 was included in this analysis. Demographic, medical
assessment and treatment data were all collected as part
of routine care through the standardized forms, and
entered weekly into the EMR via computer interface to a
central, backed up server. All vital signs, including blood
pressure, were taken during visits by either the govern-
ment clinician, or clinic support workers trained and
provided by BHOMA. Clinic support workers were
trained to take blood pressure using an appropriate
sphygmomanometer with a cuff of at least 40 % the arm
circumference in width, with the patient sitting in an
upright position after a period of rest. At BHOMA’s
inception, all study clinics were provided with such
digital blood pressure monitors. More details on
program implementation and data capture methods are
described elsewhere [17, 19].
Analysis
The primary outcome was hypertension by measure-
ment, defined as either measured systolic blood pres-
sure (SBP) ≥140 mmHg, diastolic blood pressure
(DBP) ≥90 mmHg, or prescription/reported use of an-
tihypertensive medication.
To provide insight into the discrepancy between actual
measured hypertension burden and recognized hyperten-
sion burden by healthcare workers, a person was classified
as having hypertension by diagnosis if a healthcare worker
formally recorded a diagnosis of hypertension in that
patient’s medical record, or prescribed an antihypertensive
agent. The presence of diabetes mellitus, heart failure, and
stroke were extracted from the medical record as well.
The prevalence of hypertension was calculated as a
proportion with 95 % confidence intervals.
As a secondary outcome to analyze treatment practices,
prescribed antihypertensive medications were examined
for people with hypertension by measurement. We
calculated the proportion of people that had a prescribed
drug at their first visit. Analysis was also performed for
the subset of people who had uncontrolled hypertension,
which we defined as people prescribed antihypertensive
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medication with an elevated BP measurement. Controlled
hypertension was defined as people on medication with a
normal BP measurement. Bivariate analysis of independ-
ent variables such as demographic and treatment charac-
teristics, for the outcome of uncontrolled versus
controlled hypertension, was completed using a Chi
square test with a p value of <0.05 as statistically
significant.
To account for the confounding effect of age, age
standardized prevalence of hypertension was estimated
using direct standardization methods. That is, observed
prevalence of hypertension for each age strata were
multiplied by the WHO World Standard’s weights for
each stratum, and summed together to calculate the age
standardized prevalence of hypertension [20].
In order to understand the effect of repeat visits on calcu-
lation of hypertension prevalence, a sensitivity analysis was
performed using data from all visits by adults ≥25 years,
rather than the first visit alone, to calculate the age stan-
dardized prevalence. An individual was classified as hyper-
tensive if the median of all BP measurements across visits
was either SBP ≥140 or DBP ≥90, or if they were ever pre-
scribed antihypertensive medication.
Lastly, multivariable logistic regressions were built for
two outcomes: 1) hypertension among all patients, and 2)
hypertension control among patients on antihypertensive
medications (as defined above). The predictors age, gen-
der, and body mass index (BMI) were included as
categorical independent variables; smoking was not
included as this data was not collected. Visits missing
any of the independent variables were dropped. First,
only main effects of the independent variables were
included. Second, comparisons of the predicted and
actual crude prevalence of hypertension within each
strata were compared to determine if there was a
possibility of interaction between two variables. Third,
final models including main effects and all interactions
were built for independent variables, as the effect of age
and BMI were hypothesized to be dependent on the
patient gender. Odds ratios (OR) from these final models
are presented for the predictor variables, and the log of
the ratio of odds ratios are presented for the interaction
terms. All analyses were performed in Stata/SE 13.1
(StataCorp, College Station, TX).
Ethics statement
This study was approved by the Biomedical Research
Ethics Committee at the University of Zambia and the
Biomedical Institutional Review Board at the University
of North Carolina at Chapel Hill. For individual patients
presenting to BHOMA clinics, the requirement for in-
formed consent was waived for use of these de-identified
routinely collected program data by both regulatory
bodies. The authors confirm that all ongoing and related
trials for this intervention are registered. BHOMA is
registered at ClinicalTrials.gov, Identifier: NCT01942278.
Results
Between January 2011 and December 2014, a total of
1,021,530 visits were documented at 46 participating
BHOMA health facilities. Of these, 318,384 (31.2 %)
were primary care visits by adults ≥25 years. After
excluding repeat visits and first visits without a BP
measurement, a total of 116,130 first visits by adults
were left (median number of visits: 1; interquartile range:
1,2). This comprised our analysis cohort (Fig. 1). A total
of 48,843 (42.1 %) adults in the cohort made more than
one visit.
Fifty seven percent of patients were female, with an
overall mean age of 40 years dominated by younger
participants under 45 (69.7 %). Most patients (71.6 %) had
a body mass index (BMI) <25 kg/m2 (Table 1). Our adult
study population was significantly older (mean 40 years,
median 36 years) compared to the overall population
(mean 20 years, median 18 years) that presented to
BHOMA facilities in the study timeframe.
Hypertension prevalence
The crude prevalence of hypertension by measurement
was estimated as 23.1 % [95 % CI: 22.8-23.3]. In contrast,
the crude prevalence of hypertension by diagnosis was
Fig. 1 Study Cohort
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5.6 % [95 % CI: 5.4-5.7]. On average, the age standardized
prevalence of hypertension by measurement was 28.0 %
[95 % CI: 27.7-28.3]. When we compared crude versus age
standardized estimates, age standardized prevalence was
consistently higher across all categories (Table 1). The
sensitivity analysis performed using data from all visits by
adults ≥25 years, rather than only the first visit, resulted in
a slightly lower age standardized prevalence of 26.7 %
[95 % CI: 26.4-27.0].
Figure 2 presents the crude prevalence of hypertension
by age group and gender. Although males had a higher
prevalence of hypertension compared to females at
lower age strata, by the age band 40–44, this trend
reversed. For hypertension by diagnosis, females had a
higher prevalence than males across all age bands.
Documented comorbidities, such as diabetes mellitus
type II, or expected complications of chronic hyperten-
sion such as congestive heart failure and stroke, were
extremely low at less than 1 % of people each.
In the logistic regression, increases in age or BMI
category were associated with stepwise increases in the
OR of hypertension (Additional file 1: Table S1). Male
gender was found to have a 1.54 OR [95 % CI: 1.39-1.69]
of hypertension compared to females. Interestingly, the
interaction terms for age and gender revealed that
although males had a higher OR than females at younger
Table 1 Prevalence of hypertension in 116,130 patients presenting to rural health facilities by background characteristics, Zambia
Characteristic (unit) Age, mean (SD) Number of Patients,
n (% of total)
Crude prevalence of hypertension,
n (% of row)
Age standardized prevalence of
hypertension, % [95 % CIa]
Age (years) –
25-34 – 46,547 (40.1) 6497 (14.0) –
35-44 – 34,406 (29.6) 6761 (19.7) –
≥45 – 35,177 (30.3) 13,537 (38.5) –
Sex
Females 40 (13.9) 66,138 (56.9) 15,635 (23.6) 29.7 [29.3, 30.0]
Males 41 (13.9) 49,992 (43.1) 11,156 (22.3) 25.8 [25.4, 26.2]
BMI (kg/m2)
<18.5 43 (15.6) 16,820 (14.5) 2812 (16.7) 18.3 [17.6, 18.9]
18.5-24.9 39 (13.5) 66,362 (57.1) 13,299 (20.0) 25.4 [25.0, 25.7]
25.0-29.9 42 (13.4) 15,964 (13.7) 4925 (30.8) 36.0 [35.2, 36.8]
≥30 43 (12.8) 7377 (6.4) 3152 (42.7) 46.6 [45.4, 47.7]
Total 40 (13.9) 116,130 26,791 (23.1) 28.0 [27.7, 28.3]
aCI confidence interval
Fig. 2 Prevalence of hypertension by age group and sex. Hypertension by measurement. Females represented by gray solid bars, males
represented by black outline bars
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age categories (25–34 years) for hypertension, this effect
reduced with age. For age band 35–44 years, the log
ratio of OR was 0.78 [95 % CI: 0.72-0.85] compared to
the younger age band, while for age ≥45 years the log
ratio of OR was 0.51 [95 % CI: 0.48-0.55], suggesting
females are more likely than males to have hypertension
in this older range. Interaction terms for age and BMI,
or BMI and gender, were not statistically significant.
Hypertension treatment
Antihypertensive medications prescribed to patients at the
BHOMA primary health centers are listed in Table 2. Out
of 26,791 people who had hypertension by measurement,
18.0 % were prescribed at least one antihypertensive drug.
The most commonly prescribed medications include
nifedipine (8.9 %) and furosemide (8.3 %).
When we examined blood pressure measurements
among those reportedly on antihypertensive medication,
we found that nearly 90 % remained hypertensive by
measurement (Table 3). Individuals with uncontrolled
hypertension were more likely to be female, older, and
have a higher BMI when compared to those who were
normotensive on medication. The proportion of individ-
uals with uncontrolled hypertension who had a recorded
medical history of high blood pressure was almost twice
the proportion of individuals with controlled blood pres-
sure and a recorded history (40.2 % vs 20.7 %, p < 0.0001).
Antihypertensive drug prescription was not significantly
different across most drug types in the uncontrolled com-
pared to the controlled groups, except for nifedipine
(52.0 % vs 27.4 %, p < 0.0001) and propranolol (12.9 % vs
19.5 %, p = 0.0001).
In the logistic regression, increases in age and BMI
category were associated with a trend of decreased OR
of hypertension control, although most ORs were not
statistically significant (Additional file 2: Table S2).
Age ≥45 years was associated with a 0.25 OR [95 % CI:
0.095-0.67] of control compared with age 25–34 years,
while BMI ≥30 kg/m2 was associated with a 0.20 OR
[95 % CI: 0.048-0.81] compared with BMI <18.5 kg/m2.
Male gender was not associated with an increased OR of
control compared to females [95 % CI 0.67-3.45]. None of
the interaction terms were statistically significant.
Discussion
In our rural primary care setting, similar to other studies
in the region, we observed a high prevalence of hyperten-
sion among adults seeking care. Increasing age and BMI
were associated with increased OR of hypertension. Male
gender was associated with increased OR only in the
youngest age band, with a lower OR in older age bands
compared to females. Treatment coverage was low with
only 18 % of patients with hypertension prescribed
medication. Individuals with uncontrolled hypertension
were more likely to be female, had higher BMIs, and
interestingly more likely to be prescribed nifedipine
compared to those with controlled hypertension. How-
ever, in multivariable regression, only the highest age cat-
egory ≥45 years and BMI category ≥30 kg/m2 were
associated with a statistically significant decreased OR of
hypertension control.
This study had several limitations. First, external validity
is a concern since our study sampled individuals who
sought healthcare at primary care facilities, rather than
the population as a whole. Consequently, certain results
such as the age standardized prevalence of hypertension
may be lower than a community age standardized
prevalence. Second, only data from the first visit was used
from the longitudinal dataset to arrive at prevalence.
Similar to other cross sectional studies, BP measurements
from one visit may be spuriously elevated, leading to an
overestimation. This trend was evident when we con-
sidered the median BP over all visits; in that sensitiv-
ity analysis, the overall age-standardized prevalence of
hypertension was slightly lower compared to first-visit
measurements only. Third, the specific indication for
a prescribed drug was not known—for example, we
could not confirm from the data whether a loop
Table 2 Antihypertensive medications prescribed for people with hypertension in rural health facilities, Zambia
Antihypertensive Medication Category People with hypertension (n = 26,791)
n (%)
atenelol beta blocker 477 (1.8)
enalapril angiotensin converting enzyme inhibitor 33 (0.12)
furosemide loop diuretic 2232 (8.3)
hydralazine vasodilator 51 (0.19)
hydrochlorothiazide amiloride thiazide and potassium-sparing diuretic 41 (0.15)
methyldopa alpha2 agonist 222 (0.83)
nifedipine calcium channel blocker 2394 (8.9)
propranolol beta blocker 656 (2.4)
Any antihypertensive 4833 (18.0)
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diuretic was prescribed for heart failure or hyperten-
sion. Fourth, key independent variables for inclusion in
the regression models (smoking status, family history of
hypertension, diet, exercise) were not collected as part of
the study. These were balanced against the study’s
strengths. Data collected at health facilities represented
how closely health centers put theoretical guidelines into
practice, and are more relevant for informing interven-
tions integrated into existing infrastructure. In addition,
calculation of age standardized prevalence allowed com-
parison to other prevalences standardized to the WHO
World Population.
Within Zambia, our crude prevalence of 23.1 % was
lower than the crude prevalence found in previous studies
in Lusaka urban district of 34.8 % (38.0 % male, 33.3 %
female), but closer to the proportions found in rural
Kasama district of 30.3 % (31.3 % male, 29.5 % female),
and rural Kaoma district of 25.8 % (27.5 % male, 24.6 %
female) [12, 13]. The difference between Lusaka urban dis-
trict and our data was likely due to our rural sample,
which presumably has fewer dietary and lifestyle risk
factors for developing high blood pressure than urban
samples [1, 15]. The prevalence of hypertension in sub-
Saharan Africa has ranged from 10–55 % [14, 15]. Our
crude prevalence was slightly lower than the urban areas
in neighboring countries Zimbabwe (33.3 %) and South
Africa (25.0 %), but higher than rural areas in South Africa
(10.5 %) [1, 21]. Differences in sampling, or underlying
population age and gender distributions, may have
contributed to the wide range of reported crude
prevalences. Our age standardized prevalence of 28.0 %
was similar to the age standardized levels reported by the
Millenium Villages in rural Malawi, Rwanda, and Tanzania
(22.8 % hypertension) [22].
Similar to other studies in rural sub-Saharan Africa, our
proportions for hypertension by measurement were higher
in females than males—especially in older age bands. A
meta-analysis showed 8 out of 13 total rural African
communities found a higher hypertension prevalence in
females compared to males [14]. The location of the effect
in older age bands, compared to the younger groups, is
consistent with research in other world regions [23, 24]. It
is thought that older, postmenopausal women lose the
protective role of ovarian estrogen on vasodilation and
decreased sympathetic activity, thereby resulting in an
elevated BP [25]. Female predominance was also more
apparent in the hypertension by diagnosis, which is
consistent with prior research demonstrating females were
more likely to have been detected, to be on treatment, and
have hypertension controlled compared to males [14].
Table 3 Differences in characteristics of patients on antihypertensive medications, by hypertension control status
Characteristic (unit) Uncontrolled Hypertension (n = 4340) Controlled Hypertension (n = 493) p value
n (%)
Female 3175 (73.2) 339 (68.8) 0.038
Age (years) <0.0001
25–34 353 (8.1) 113 (22.9)
35–44 786 (18.1) 103 (20.9)
≥45 3201 (73.8) 277 (56.2)
BMI (kg/m2) <0.0001
<18.5 328 (7.6) 47 (9.5)
18.5-24.9 1634 (37.6) 220 (44.6)
25.0-29.9 1000 (23.0) 104 (21.1)
≥30 831 (19.1) 59 (12.0)
History of hypertension 1747(40.2) 102 (20.7) <0.0001
Treatments
atenelol 439 (10.1) 38 (7.7) 0.09
enalapril 28 (0.65) 5 (1.0) 0.35
furosemide 2007 (46.2) 225 (45.6) 0.80
hydralazine 45 (1.0) 6 (1.2) 0.71
hydrochlorothiazide amiloride 34 (0.78) 7 (1.4) 0.14
methyldopa 205 (4.7) 17 (3.4) 0.20
nifedipine 2259 (52.0) 135 (27.4) <0.0001
propranolol 560 (12.9) 96 (19.5) 0.0001
Controlled hypertension: on antihypertensive medications with a normal blood pressure measurement (<140/90). Uncontrolled hypertension: on antihypertensive
medications without a normal blood pressure measurement
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Females have more touch points with the healthcare
system through antenatal care visits and have better health
seeking behavior, meaning they may present more
frequently to health centers and be more likely than males
to be detected [14, 26, 27]. Indeed, in BHOMA the
majority of patients were females (57 % of study cohort vs
51 % of population) [28].
Another major finding in our study was the under- and
improper treatment of hypertension. Zambian national
guidelines, consistent with the Eighth Joint National
Committee criteria, state that after unsuccessful lifestyle
modification, antihypertensive treatment should start with
one agent (hydrochlorothiazide-amiloride or a calcium
channel blocker), with increasing doses or combinations if
BP remains elevated [29, 30]. Almost all classes of antihy-
pertensive drugs are on the essential medicines list and
provided free in Zambian government clinics, including
thiazides, calcium channel blockers, and ACE inhibitors.
A major contributor to under-treatment seemed to be
under-diagnosis; another contributing factor may have
been healthcare worker discomfort with chronic diseases,
as 50.7 % of Zambian government health workers feel a
lack of expertise in managing hypertension [31]. While
under-treatment certainly contributes to persistent hyper-
tension, even the vast majority of treated patients had
uncontrolled hypertension. Possible reasons include lack
of awareness in the general population about dietary salt
contributions to elevated BP, poor patient adherence or
clinic attendance for refills, and improper treatment
choices by clinic staff. Furosemide was commonly used (in
8 % of hypertensive patients), which is only recommended
in the presence of renal or cardiac failure [32]. Given the
extremely low numbers of documented cardiac failure in
our sample, it is unlikely that patients were evaluated for
these conditions at the primary care level, and thus
unlikely to be on furosemide for correct indications.
Improper treatment is likely tied to many factors, includ-
ing medication stock outs and lack of training in best
practices.
Our study showed the high prevalence of hypertension
in Zambian primary care clinics and the need for early
intervention. Given limited resources, interventions should
focus on population-level and individual-level public health
approaches in parallel. Passing national legislation on
hypertension risk factors (tobacco, alcohol, poor diet) may
have a cost effective yet considerable public health impact.
Modeling in LMIC shows that a 33 % tax on tobacco could
result in only US$ 3–42 spent per DALY averted from car-
diovascular disease due to decreased smoking [33]. At the
individual level, emphasis must be placed on identifying
those at highest risk and ensuring proper treatment. The
WHO and International Society of Hypertension have
developed low resource wall charts of the Framingham
cardiovascular risk calculator, requiring only gender, SBP,
smoking status, and diabetes mellitus type II status
[34]. Treating only patients with a total cardiovascular
risk of >15 % in primary prevention can be cost ef-
fective at US 790-930 per DALY averted, and is cost
saving for secondary prevention [33]. Our study also
demonstrated individuals were being treated with the
ineffective drug furosemide, suggesting the need for
broader health systems strengthening in prescribing
practices and drug stock outs. There remain many
unanswered questions about hypertension in Zambia,
including reasons for the poor screening and treat-
ment in the BHOMA clinics (despite its objective to
improve quality of care through structured protocols),
treatment practices at higher hospital levels of care,
and evaluation of NCD training and practices. Future
studies will need to explore reasons for hypertension
under-treatment to develop sustainable interventions for
primary and secondary prevention of cardiovascular
disease.
Conclusions
In summary, in our rural Zambian primary care setting,
the age standardized prevalence of hypertension was
high at more than one-quarter of adults aged ≥25 years.
Consistent with other studies, females were noted to
have a higher prevalence than males especially at older
ages, likely due to greater engagement with the health
system and menopausal status. Treatment coverage was
low, with evidence of improper prescriptions for those
who were treated. To prevent progression of hyperten-
sion to cardiovascular mortality, future interventions
should implement dual population preventive care and
high risk individual strategies.
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